Detecting early signs of aggressive tumors in patients with neurofibromatosis type I.
Official title: Use of Noninvasive Biomarkers and Advanced MRI for early detection of NF1-associated MPNSTs
Funded at University of Tx Md Anderson Can Ctr · NIH-11053473 · Data updated 2026-11-12
This study is looking for better ways to spot nerve tumors early in people with neurofibromatosis type I by using simple blood tests and advanced MRI scans, so patients can avoid painful biopsies and get the help they need sooner.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | March 11, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $530,632 |
| NIH project number | 5R01CA285980-02 |
| Project ID | NIH-11053473 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with neurofibromatosis type I who are at risk for developing malignant peripheral nerve sheath tumors.
✕Less likely to help
Patients without a diagnosis of neurofibromatosis type I or those who do not have a risk of developing MPNSTs may not benefit from this research.
What this research studies
This research focuses on improving the early detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type I (NF1) using noninvasive biomarkers and advanced MRI techniques. The study aims to develop a diagnostic panel that includes DNA methylation markers and tumor profiles derived from cell-free DNA, which can be used alongside imaging methods to accurately identify MPNSTs. By utilizing these innovative approaches, the research seeks to provide a more effective and less painful alternative to traditional diagnostic methods, such as biopsies. The ultimate goal is to enhance early diagnosis and treatment monitoring, leading to better patient outcomes.
Why it matters
Potential benefit: If successful, this research could significantly improve the early detection and management of aggressive tumors in NF1 patients, potentially increasing survival rates.
How similar studies have gone: Previous research has shown promise in using biomarkers for cancer detection, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Torres, Keila Enitt — University of Tx Md Anderson Can Ctr
- Study coordinator: Torres, Keila Enitt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.